Perspective Therapeutics’ (CATX) Buy Rating Reiterated at BTIG Research

BTIG Research reiterated their buy rating on shares of Perspective Therapeutics (NASDAQ:CATX) in a report released on Tuesday,Benzinga reports. They currently have a $14.00 price target on the stock.

Several other analysts have also weighed in on the stock. B. Riley lowered their price objective on shares of Perspective Therapeutics from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday, November 18th. Truist Financial began coverage on shares of Perspective Therapeutics in a report on Monday, November 24th. They issued a “buy” rating and a $12.00 price target for the company. Finally, UBS Group dropped their price objective on shares of Perspective Therapeutics from $18.00 to $7.00 and set a “buy” rating on the stock in a report on Friday, November 21st. Four research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $11.00.

Perspective Therapeutics Stock Down 5.3%

NASDAQ CATX opened at $2.48 on Tuesday. The company has a market cap of $184.36 million, a P/E ratio of -2.76 and a beta of 1.18. Perspective Therapeutics has a one year low of $1.60 and a one year high of $5.39.

Hedge Funds Weigh In On Perspective Therapeutics

A hedge fund recently bought a new stake in Perspective Therapeutics stock. Auctus Advisors LLC purchased a new stake in shares of Perspective Therapeutics (NASDAQ:CATX) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 31,673 shares of the company’s stock, valued at approximately $87,000. Perspective Therapeutics comprises 0.1% of Auctus Advisors LLC’s portfolio, making the stock its 26th biggest position. Institutional investors and hedge funds own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Isoray, Inc, through its subsidiary, IsoRay Medical, Inc, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities.